View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 27, 2020

Philips receives clearance for biosensor to monitor Covid-19 patients

Royal Philips has received 510(k) clearance from the US Food and Drug Administration (FDA) for its wearable biosensor, Philips Biosensor BX100, to help monitor Covid-19 patients in hospitals.

Royal Philips has received 510(k) clearance from the US Food and Drug Administration (FDA) for its wearable biosensor, Philips Biosensor BX100, to help monitor Covid-19 patients in hospitals.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Designed to address a new approach to vital signs measurements, the lightweight, disposable biosensor is a five-day single-use wearable patch.

It can be discreetly attached to the chest to collect, store, measure and transmit respiratory rate and heart rate every minute along with other contextual parameters such as posture, activity level and ambulation.

Philips Biosensor BX100 was designed for use by healthcare professionals on patients 18-years-old and older, the company noted.

The device will advance clinical surveillance in the Philips patient deterioration detection solution that also incorporates IntelliVue GuardianSoftware for early warning scoring and EarlyVue VS30 advanced patient monitors.

It will enable clinicians to help improve patient care in lower acuity care areas by detecting risk and making early interventions possible.

The company noted that the OLVG Hospital in the Netherlands is currently using the solution to help manage the triage and clinical surveillance of confirmed and suspected Covid-19 patients.

Philips Monitoring and Analytics general manager Peter Ziese said: “During this unprecedented time of Covid-19, the Philips Biosensor BX100 helps provide rapid deployment for clinical surveillance to help decrease the risk of exposure of healthcare workers while acquiring frequent patient vitals and easing the demand for personal protective equipment (PPE).

“The biosensor is an integral component in our patient deterioration detection solution, which helps in the identification of the subtle signs of deterioration in a patient’s condition at the point of care, hours before a potential adverse event would occur.”

The Philips wearable biosensor is part of the company’s portfolio of solutions to address patient deterioration, supporting general care around the world with smart clinical intelligence.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network